Novo Nordisk
LeaveRussia detail: Scaling Back
Novo Nordisk is a Danish pharmaceutical company.
Business in Russia
Danish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year.
Decision trail
Decision date 23/05/2023 · Reference ↗
Suspend further marketing and clinical investment; pause new clinical trials and active enrollment but increased revenue in Russia in 2022 vs 2021. Danish diabetes care giant Novo Nordisk (NOV: N) has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of year 2024. Revenue decreased in 2024 vs 2023 by more than -10%.
Local stats (LeaveRussia)
Status history since 2022
- 03/08/2026 — scaling back · Imported from KSE LeaveRussia
Exposure profile
Full exposure profile is a Professional feature
Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.
Upgrade to Professional